Aardvark Therapeutics, Inc. (AARD) stock
AARDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.91−0.24 (-20.87%)
Close on Nov 18, 2026Market cap $19.92MP/E –Yield –
Aardvark Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Aardvark Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$73.96M. For fiscal 2025 it was -$62.73M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$62.73M | – |
| FY2024 | Dec 31, 2024 | -$22.79M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.46M | – |
| Q4 FY2025 | Dec 31, 2025 | -$18.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$15.85M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$9.45M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.09M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.07M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.17M | – |
See a number that looks wrong?